title: Peri-procedural care of renal nerve ablation candidates.
abstract: Percutaneous catheter-based transluminal renal nerve ablation (RNA) by delivery of radiofrequency energy constitutes a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RNA. In this review we summarize current recommendations for appropriate patient selection for RNA and multimodal strategies in order to optimize pharmacological treatment for resistant hypertension. The safety and efficacy of the RNA based on published trials are also presented. Furthermore, a detailed description of the periprocedural management, the methodology of the RNA procedure and appropriate follow-up are provided. In conclusion, in order to improve the overall clinical outcome and achieve optimal management of resistant hypertensive patients before and after the RNA, experienced and certified centers are of major importance.
authors.affiliation: First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece. ktsioufis@hippocratio.gr
authors.forename: Costas
authors.initials: C
authors.lastname: Tsioufis
authors.forename: Kyriakos
authors.initials: K
authors.lastname: Dimitriadis
authors.forename: Costas
authors.initials: C
authors.lastname: Thomopoulos
authors.forename: Dimitris
authors.initials: D
authors.lastname: Tsiachris
authors.forename: Alexandros
authors.initials: A
authors.lastname: Kasiakogias
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Kintis
authors.forename: Dimitris
authors.initials: D
authors.lastname: Flesas
authors.forename: Vasilios
authors.initials: V
authors.lastname: Papademetriou
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D017115:Catheter Ablation / Q000379:methods*; D004351:Drug Resistance; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D007668:Kidney / Q000294:innervation; D018579:Patient Selection; D013562:Sympathectomy / Q000009:adverse effects / Q000379:methods*; D013564:Sympathetic Nervous System / Q000601:surgery
chemical_list: D000959:Antihypertensive Agents